Clips
Lists
Grabien Mobile App
Get Grabien on the go!
Live News
  Collapse  
The Wire

Provention Bio's Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops

Jul 6, 2021 7:55 AM
The FDA has issued a Complete Response Letter (CRL) to Provention Bio Inc's (NASDAQ:PRVB) teplizumab...
Source: Markets Insider
Like our work? Support the cause.
$
/